Delays in treatment escalation after failure in multiple sclerosis: the role of therapy type and healthcare system
In a study of 288 patients with relapsing-remitting MS, the median time from failure identification to subsequent therapy initiation was noted to be 142.0 days. Factors like insurance type influenced these delays, with private insurance showing the longest delay for high-efficacy treatment initiation (211.0 days) and public systems showing a significant difference between high-efficacy and non-high-efficacy treatments (165.0 vs. 66.0 days).
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
This study highlights substantial delays in treatment initiation following therapeutic failure, emphasizing the impact of therapy type and healthcare coverage on patient care, which may inform future healthcare policies.
What this does not prove
The study does not explore how delays may differ across patient demographics or geographic locations. Additionally, real-world variations may affect the generalizability of these results.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 288 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Yes
- Relevant MS type
- Not reported
- Publication date
- 2026-10-17
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceDelays in treatment escalation after failure in multiple sclerosis: the role of therapy type and healthcare system. ↗DOI: 10.1007/s10072-026-09483-6
Supporting passages (10)
study designretrospective observational study using a real-world registry of patients with relapsing-remitting MS.
subjectspatients with relapsing-remitting MS.
sample sizeA total of 288 patients were included.
primary endpoint metMedian time to treatment initiation was 142.0 days (IQR 89.0-247.0).
publication datePublication date: 2026-10-17
interventionCONCLUSION: Treatment initiation delays after therapeutic failure were substantial and varied according to treatment category and healthcare coverage.
comparatorThe longest median time to HET initiation was observed with private insurance (211.0 days), whereas the largest within-system difference between HET and non-HET was observed in the public system (165.0 vs.
primary endpointtime from failure identification to initiation of subsequent therapy.
findingsTreatment initiation delays after therapeutic failure were substantial and varied according to treatment category and healthcare coverage.
limitationsTitle: Delays in treatment escalation after failure in multiple sclerosis: the role of therapy type and healthcare system.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.